4- (2- chlorophenyl)- 2- (2- (4- isobutylphenyl)ethyl)- 6,9- dimethyl- 6H- thieno(3,2- f)(1,2,4)triazolo(4,3- a)(1,4)diazepine

06/01/1992 - "Thus, Y-24180 may be useful for the treatment of asthma."
01/01/1997 - "Therefore, Y-24180 would be a clinically promising drug for the treatment of bronchial asthma."
10/01/1995 - "Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma."
10/01/1995 - "To determine whether PAF is involved in BHR in humans, we carried out a randomized, double-blind, placebo-controlled, two-phase cross-over study on the effects of Y-24180, a potent, specific, orally active PAF receptor antagonist, on BHR to methacholine in patients with asthma. "
04/01/1997 - "The data indicate practical participation of PAF in the development of antigen-induced asthmatic responses in animals, and usefulness of Y-24180 in the clinical treatment of asthma as well as other anti-asthmatic drugs."

01/26/2001 - "The present study showed that a PAF receptor antagonist, Y-24180, has the preventive effect against CsA-induced acute renal failure, which indicates that PAF may partly be involved in the mechanism of renal vasoconstriction induced by CsA. "
01/26/2001 - "To evaluate the effect of Y-24180, a potent and long-acting antagonist to platelet-activating factor (PAF) receptors, on cyclosporine A (CsA)-induced acute renal failure, the influence of its pretreatment on the CsA-induced alterations in renal hemodynamics was examined in male Wistar rats under anesthesia. "

02/19/1996 - "To study the role of PAF and TXA2 in radical production during cerebral ischemia-reperfusion, we evaluated the effects of a PAF antagonist, Y-24180, and a TXA2 antagonist, S-1452, on radical formation in rats with 1 h middle cerebral artery (MCA) occlusion. "

05/01/1997 - "Orally administered Y-24180 and WEB 2086 both dose-dependently prevented PAF-induced airway hyperresponsiveness (ED50: 0.0010 and 0.019 mg/ kg, respectively) and bronchoconstriction (ED50: 0.0014 and 0.024 mg/kg, respectively) in guinea pigs. "
04/01/1997 - "Under oral administration before or after the challenge with antigen, Y-24180, OKY-046, and ONO-1078 suppressed the antigen-induced airway hyperresponsiveness. "

11/01/2000 - "Therefore, Y-24180 is expected to contribute to the treatment of inflammatory skin diseases including atopic dermatitis."